Table 1. On-going clinical trials.

Treatment	ClinicalTrials identifier	Phase	Patient population	Selected eligibility requirements	Primary endpoint
Olaparib	NCT02677038	II	At least one prior chemotherapy in the metastatic setting	Germline BRCA1/2 negative. Previously identified genetic aberrations associated with HRD will be eligible, e.g., somatic BRCA mutation, FA gene or RAD51 mutations	Response rate
Olaparib vs. placebo	NCT02184195	III	Non-progression after at least 12 weeks of platinum-based chemotherapy	Germline BRCA1/2 mutation	Progression-free survival
Irinotecan, cisplatin, mitomycin-C ± olaparib	NCT01296763	I	First-line	Unselected	Dose finding
Cediranib + olaparib	NCT02498613	II	At least one prior chemotherapy in the metastatic setting	Mixed disease cohort, BRCA mutation excluded	Response rate
Rucaparib	NCT02042378	II	At least one but not more than two prior lines of chemotherapy	Germline or somatic BRCA1/2 mutation	Response rate
Olaparib	NCT02511223	II	At least one prior chemotherapy in the metastatic setting	Tested negative for germline BRCA1/2; previously identified loss of ATM by IHC or family history of BRCA-associated cancers; previously identified genetic aberrations associated with HRD will be eligible, e.g., somatic BRCA mutation, FA gene or RAD51 mutations	Response rate
Gemcitabine + veliparib + IMRT	NCT01908478	I	Unresectable disease	Unselected	Dose finding
Gemcitabine + cisplatin ± veliparib	NCT01585805	II	Part 1: first-line metastatic setting; Part 2: single agent in previously treated disease	Confirmed BRCA1/2 or PALB2 mutation	Response rate
mFOLFOX6 + veliparib	NCT01489865	I/II	First-line	Confirmed BRCA1/2, PALB2 of FA gene mutations	Dose finding

IMRT, intensity-modulated radiation therapy; HRD, homologous recombination deficiency; ATM, ataxia telangiectasia mutated.